#7 - Exelixis (NASDAQ:EXEL)
It’s been a good year for biotechnology stocks. However, one stock that may not get enough attention is Exelixis Inc. (NASDAQ: EXEL). But if you’re unfamiliar with this mid-cap stock, now may be a good time to see what you’re missing.
The company is an oncology-focused biotech company that has two commercially available products. CABOMETYX is an oral tablet for advanced renal cell carcinoma post-anti-angiogenic therapy. COMETRIQ is an oral tablet used to treat progressive and metastatic medullary thyroid cancer. The company will be protected from patent expiration until 2030. And during that time, it’s likely to bring one of the four candidates that are in Phase 3 clinical trials to market. And the company’s pipeline goes deeper than that.
The Biden administration has made finding a cure for cancer an imperative of the U.S. government. That focus is likely to continue no matter who occupies the Oval Office. Analysts are bidding EXEL stock higher before it reports earnings in late October.
About Exelixis
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Read More - Current Price
- $33.34
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $32.44 (2.7% Downside)
Election years bring uncertainty and investors hate uncertainty. As it relates to the presidential election, the known is always better than the unknown. That's why market volatility tends to recede in the two months following the presidential election. Once investors know who will occupy the White House and equally important which party will control the House and Senate, investors can start to forecast public and monetary policy.
Not surprisingly, investors would prefer gridlock. Gridlock is a state where different political parties rule the executive and legislative branches. It makes it harder to get things done, which is frustrating for many Americans but music to the ears of private-sector companies.
What will 2024 bring? We don't know, but we know that there will be opportunities for investors who are willing to take what the market gives them. The seven stocks in this presentation are all expected to outperform the market in 2025 and, in many cases, have catalysts for years to come.
More Investing Slideshows:
